News & Updates

Show Multimedia Only

Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect

20 Sep 2025 by

A low-dose combination therapy, AD-209, that includes telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 6.25 mg demonstrates efficacy in lowering high blood pressure (BP) when compared with telmisartan alone in patients with essential hypertension, reports a study presented at ESC 2025.

Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect

20 Sep 2025

Beta-blockers efficacious in myocardial infarction with mildly reduced LVEF

19 Sep 2025

In the treatment of patients with myocardial infarction (MI) with mildly reduced left ventricular ejection fraction (LVEF), beta-blockers appear to cut the risk of mortality, new MI, and heart failure, according to a study.

Beta-blockers efficacious in myocardial infarction with mildly reduced LVEF

19 Sep 2025

Statins may protect adults with T1DM against all-cause death, CVD

19 Sep 2025

The use of statins for primary prevention in adults with type 1 diabetes mellitus (T1DM) appears to prevent all-cause mortality and major cardiovascular disease (CVD), with an acceptable safety profile, a study has shown.

Statins may protect adults with T1DM against all-cause death, CVD

19 Sep 2025

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

19 Sep 2025 by

Treatment with inclisiran, on top of individually optimized lipid-lowering therapy (ioLLT), resulted in the achievement of guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets among patients with hypercholesterolaemia at high or very high risk of cardiovascular (CV) events, according to the VICTORION-Difference trial presented at ESC 2025.

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

19 Sep 2025

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

18 Sep 2025 by

Among women who have previously had an ischaemic stroke, the use of vaginal estradiol tablets does not raise the risk of having another stroke, according to new research.

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

18 Sep 2025

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

18 Sep 2025 by

Many patients with cirrhosis and acute kidney injury (AKI) need 2 days to show response to albumin treatment, a study has found. Therefore, reducing the duration of albumin therapy may result in overtreatment with terlipressin.

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

18 Sep 2025

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

18 Sep 2025

The addition of pembrolizumab to the combination of gemcitabine and cisplatin does not appear to worsen the health-related quality of life (HRQoL) in patients with advanced biliary tract cancer (BTC), results of the phase III KEYNOTE-966 study have shown.

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

18 Sep 2025

Transforming Obesity Care: Insights from Experts on Semaglutide 2.4 mg

18 Sep 2025

With the launch of semaglutide 2.4 mg (Wegovy) in Singapore, a new chapter in the pharmacological treatment of obesity begins. MIMS Doctor spoke with two leading experts: Professor David Lau, an endocrinologist and Professor Emeritus of Medicine at the University of Calgary Cumming School of Medicine, Canada, and a key contributor to the 2020 Canadian Adult Obesity Guidelines, and Dr Georgia Rigas, Senior Bariatric Medical Practitioner at St George Private Hospital, Sydney, Australia, with extensive experience in primary care obesity management. Both experts shared compelling insights on how semaglutide 2.4 mg is set to transform obesity care across clinical settings.

Transforming Obesity Care: Insights from Experts on Semaglutide 2.4 mg

18 Sep 2025

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

17 Sep 2025 by

Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

17 Sep 2025

Long-term denosumab viable in patients with rheumatic diseases

17 Sep 2025

The use of denosumab for longer durations is generally safe and effective for increasing bone mineral density (BMD) in patients with rheumatic diseases (RDs), suggests a recent study.

Long-term denosumab viable in patients with rheumatic diseases

17 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect

Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect

Beta-blockers efficacious in myocardial infarction with mildly reduced LVEF

Beta-blockers efficacious in myocardial infarction with mildly reduced LVEF

Statins may protect adults with T1DM against all-cause death, CVD

Statins may protect adults with T1DM against all-cause death, CVD

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

Vaginal estrogen tablets unlikely to increase risk of stroke recurrence

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

Transforming Obesity Care: Insights from Experts on Semaglutide 2.4 mg

Transforming Obesity Care: Insights from Experts on Semaglutide 2.4 mg

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

Long-term denosumab viable in patients with rheumatic diseases

Long-term denosumab viable in patients with rheumatic diseases